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Abstract. The combination of platelet count to mean platelet
volume (COP‑MPV) has been recently reported as a prognostic
indicator of oral cavity cancer and other cancer sites. The aim
of the present study was to validate the utility of the COP‑MPV
as a prognostic indicator in all head and neck cancer (HNC)
sites. The clinicopathological characteristics of the COP‑MPV
with HNC were also investigated. This is a retrospective
cohort study that recruited consecutively treated patients at
a tertiary level academic hospital. Clinicopathological characteristics were recorded, including the COP‑MPV scores.
Survival was analyzed using Kaplan‑Meier analysis, as well as
multivariate Cox Proportional Hazards regression. COP‑MPV
was not associated with the survival outcome in univariate
or multivariate analysis. In the multivariate model, tumor
differentiation, tumor stage, nodal stage, surgical margins and
hemoglobin were revealed to be significantly associated with
survival. The results demonstrated that the COP‑MPV is not a
suitable prognostic factor for HNC.
Introduction
Head and neck cancers (HNC) account for a significant proportion of cancers in the USA (1). HNCs are typically treated
with surgery, radiotherapy, chemotherapy, or in combination.
Single surgical treatment with or without radiation is the
standard therapy for Tumor-Node-Metastases (TNM) stages I
and II (2). On the other hand, a combination of surgery, radiotherapy, and chemotherapy may be used for more advanced
TNM stages (3). TNM staging is a widely used scoring
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system among prognostic factors for determining patient
survival (1,4). Previously, several biomarkers were studied as
serologic markers albeit low specificity and difficult clinical
application (5). As such, there is a need for finding effective
and clinically efficient biomarkers purposed as prognostic
factors for HNCs (6‑8).
In recent studies, platelet activation was observed to be a
significant biological process for cancer occurrence and metastasis (9). Platelet (PLT) and mean platelet volume (MPV) are
typical measures of platelet activation (10), where high levels of
MPV signify irregular platelet production and activation (11). It
has also been observed that abnormal MPV levels are associated with patients with various disorders and malignant tumors.
Building on this information, several studies have recently
investigated the prognostic utility of the combination of PLT
and MPV (COP‑MPV). A recent study by Park et al (12) found
that the COP‑MPV was a significant prognostic indicator
in oral cavity cancer. Additionally, the COP‑MPV has been
found to be a prognostic indicator in non‑small cell lung
cancer (NSCLC) (13), and esophageal cancer as well (14). The
study by Park was a small sample study with only 40 patients,
and only consisted of patients with oral cavity cancer (12).
In this context, the goal of our study was to (a) evaluate the
prognostic utility of the COP‑MPV in a larger sample size, with
patients of all HNC subsites and (b) to determine the clinicopathological characteristics associated with COP‑MPV.
Materials and methods
Study design. This is a retrospective cohort study that included
consecutively‑treated patients with HNC treated at the New
York Head & Neck Institute (NYHNI) from 2009‑2016. This
study is part of a large retrospectively managed cancer database (15,16) and was approved by the Institutional Review Board
of the Northwell Health System (IRB# 17‑0280‑LHH). The
study conforms to the guidelines stupilated in the Declaration
of Helsinki. The inclusion criteria of the study included: i) histologically confirmed HNC (excluding thyroid); ii) undergoing
curative intent surgery; iii) availability of complete clinical data
and disease records. The exclusion criteria included: i) clinical
evidence of pretreatment infection, other inflammatory disease
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or comorbidity that would influence results of the platelet count;
ii) benign disease; iii) biopsies or non‑curative intent procedures
or palliative procedures; iv) lymphoproliferative malignancies;
v) incomplete medical records which include absence of preoperative complete blood count (CBC); vi) CBC that was taken
more than two weeks pre‑operatively; and vii) neoadjuvant
chemotherapy or radiation therapy. Patients were screened
with pre‑defined International Classification of Diseases (ICD)
9/10 codes and were treated according to physician discretion
consistent with contemporary treatment paradigms.
Variable selection and data collection. Various literature were
reviewed for significant prognostic factors in HNC that could be
used to generate univariate and multivariate statistical models.
The established prognostic factors for HNC used in the data
collection process included: age, sex, body mass index (BMI),
alcohol history, smoking history, eastern cooperative oncology
group (ECOG) score, and Karnofsky performance status.
All patients were retrospectively graded based on the Adult
Comorbidity Evaluation 27 (ACE‑27) score, a validated
comorbidity scoring system for head and neck cancer (17).
Treatment and tumor variables were also incorporated:
Tumor differentiation, staging (8th Edition of American Joint
Committee on Cancer System) (18), adjuvant radiation (RT),
adjuvant chemotherapy (CT), and surgical margin status. For
oropharyngeal tumors, human papillomavirus (HPV) status
was determined according to either p16 positivity via immunohistochemistry, or HPV DNA detection. In addition, CBC
markers of interest were considered as well and included: the
hemoglobin (Hb), platelet count, mean platelet volume, and
white blood cell count (WBC). Since a unified scoring system
has not been developed for the COP‑MPV, we utilized the
scoring system developed in the largest dataset published on
the COP‑MPV, by Zhang et al (14). The cutoffs for platelet
count and platelet volume were set to 212 (109/L) and 10.6 (fl)
respectively. A score of 1 was given if one of the cutoffs were
met, and a score of 2 was given if both cutoffs were met.
Patient records were retrieved electronically from the
REDCap database (19). Necessary and relevant clinical information were gathered from the patients' scanned documents. Such
documents included clinical, pathological, or laboratory reports.
CBC parameters were obtained from preoperative lab results.
Endpoint definition. Event‑free survival (EFS) was chosen as
the primary endpoint. We chose EFS as the primary endpoint
as a recent study by Michiels et al (20) had shown that the EFS
was an effective proxy for OS as the primary survival endpoint.
EFS was defined as the date of surgery to last follow‑up or
‘event’, depending on which date was earliest. An ‘event’ was
defined as any progress, local or distant recurrence, or death. If
there was no occurrence of an ‘event’ at the last follow‑up, the
patient was censored for the survival analysis.
Statistical analysis. Parametric tests such as Chi‑square tests
and t‑tests were used to evaluate the differences between the
relationship of clinicopathological features. With Kaplan‑Meier
curves (KM), EFS was estimated and log‑rank tests were
used to identify survival differences between the KM curves.
Furthermore, Cox proportional hazards model (CPH) was
used to determine the hazard ratio (HR) of the aforementioned

variables. Multivariate analyses was conducted on all variables
recorded with regards to EFS. For generating a multivariate
CPH model, backwards variable selection was used. For the
backwards multivariate model, variables with P>0.1 were
removed from the model. Hazard ratios (HR) with 95% confidence intervals (95% CI) with two‑sided P‑values are presented.
The chosen alpha level was 0.05, and all P‑values less than the
alpha level were considered statistically significant. All statistical analyses, excluding cutoff derivation, were performed
using MedCalc for Windows, version 15.0 (MedCalc Software
bvba, Ostend, Belgium).
Results
A total of 113 patients met the inclusion and exclusion criteria
for this study (Table I). The most common site of tumor was the
Oral Cavity (46%) followed by the oropharynx (18%). Of the
oropharyngeal tumors, 15 (75%) were associated with either
p16 or HPV DNA. In regards to tumor histology, the most
prominent type was squamous cell carcinoma (93 patients,
82.3%). A total of 27 (24%) patients had a COP‑MPV score
of 0, 65 (58%) of patients had score of 1, and 21 (19%) of
patients had score of 2. With regards to the clinicopathological
characteristics and COP‑MPV score, only WBC count was
associated with higher COP‑MPV values (P=0.0036, Table I).
With regards to the survival analysis, the multivariate
analysis of EFS revealed that age, sex, BMI, Karnofsky
score, ACE score, tumor differentiation, Staging‑N, WBC,
platelet count, and COP MPV were not significant prognostic
indicators (Table II). The factors associated with EFS in the
multivariable model were higher tumor grade (HR=2.37,
95% CI: 1.17‑4.84, P=0.0171), higher tumor stage (HR=8.91,
95% CI: 3.46‑22.91, P<0.0001), higher nodal stage (pN1
HR=3.41, 95% CI: 1.11‑10.47, P=0.0321; pN2 HR=3.30, 95% CI
1.23‑8.86, P=0.0177), positive surgical margins (HR=3.77,
95% CI: 1.54‑9.24, P=0.0037), and higher hemoglobin count
(HR=0.62, 95% CI: 0.50‑0.78, P<0.0001). COP‑MPV was not
associated with EFS in the multivariate survival analysis. To
confirm if COP‑MPV did not have a prognostic effect, we
performed a further Kaplan Meier analysis with a log‑rank
test. The Kaplan‑Meier analysis revealed that COP‑MPV was
not associated with EFS (P=0.3723, Fig. 1).
Discussion
The COP‑MPV scoring system was developed by combining
PLT and MPV to measure platelet activation and to assess the
prognosis of cancer patients. As such, previous studies revealed
COP‑MPV to be an ideal and effective prognostic factor for
these type of patients (12‑14). Building upon previous research
by others, this study sought to validate the prognostic value
of COP‑MPV for all HNC subsites. The results and analyses
of this study revealed that COP‑MPV was not associated with
our primary survival outcome, EFS. There were no significant
differences between COP‑MPV scores of 0,1 and 2 with
regard to EFS. Additionally, COP‑MPV was not associated
with EFS in the univariate Kaplan Meier analysis either. In our
multivariate survival analysis, we found that known factors for
survival, namely differentiation, tumor stage, surgical margins,
and hemoglobin were associated with EFS.
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Table I. Summary of cohort characteristics stratified by COP-MPV.
Variable
Age (years)
Sex
Male
Female
BMI (kg/m2)
History of alcohol use
Yes
No
History of smoking
Yes
No
ECOG score
0
1
2

Tumor primary location
Nasopharynx
Oropharynx
Oral cavity
Larynx
Salivary gland
Paranasal sinus
Cervical lymph node or unknown primary
Cutaneous
Tumor histology
Adenocarcinoma
Squamous cell carcinoma
Adenoid cystic carcinoma
Mucoepidermoid carcinoma
Basal cell carcinoma
Other
Tumor differentiation
Unable to assess
Well differentiated
Moderate differentiation
Poor differentiation
Staging pT
pT0
pT1
pT2
pT3
pT4
Staging pN
pN0
pN1
pN2
pN3
Adjuvant radiotherapy
Yes
No

COP-MPV 0a

COP-MPV 1a

COP-MPV 2a

P-value

66.48

63.23

64.048

0.6027

20
7
24.89

43
22
26.50

13
8
28.76

0.6444

12
15

33
32

12
9

0.6810

13
14

31
34

12
9

0.7426

16
9
2

50
14
1

16
4
1

0.3801

0
5
8
4
3
2
2
3

1
13
29
6
7
5
1
3

0
2
15
0
2
0

0.2692

1
21
1
1
1
2

5
52
1
1
0
6

0
20
0
0
0
1

0.6290

7
7
11
2

5
10
29
21

4
3
10
4

0.0617

2
10
11
3
1

2
25
19
11
8

2
9
6
1
3

0.6384

19
3
3
2

41
10
7
6

16
2
3
0

0.8009

12
15

27
38

4
17

0.1339

0.0655

0
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Table I. Continued.
Variable
Adjuvant chemoradiotherapy
Yes
No
Surgical margin status
Positive
Negative
WBC (109/l)
Hemoglobin (g/dl)
MPV (fl)
Platelet Count (109/l)

COP-MPV 0a

COP-MPV 1a

COP-MPV 2a

P-value

6
21

14
51

2
19

0.4420

3
24
6.51
13.39
9.66
178.33

9
56
7.56
13.30
9.81
249.88

3
18
9.16
6.81
11.25
275.14

0.9292
0.0036b
0.1356
<0.0001b
<0.0001b

Continuous variables presented as mean values and categorical variables are represented as integers; bStatistically significant at P<0.05.
BMI, body-mass index; ACE-27, adult comorbidity evaluation 27 score; ECOG, Eastern Cooperative Oncology Group score; WBC, white
blood cell count; MPV, mean platelet volume; COP-MPV, combination of platelet count and mean platelet volume score.
a

Figure 1. Kaplan Meier curve of the event‑free survival of COP‑MPV. Kaplan‑Meier curve analysis of the event‑free survival of the COP‑MPV. The log‑rank
test showed no significant differences between curves (P= 0.3723). COP‑MPV, combination of platelet count and mean platelet volume.

In comparison to other studies (12‑14), similar factors were
incorporated into the analyses of the results. This included
age, sex, tumor location, degree of differentiation, TNM stage,
WBC, platelet count, and mean platelet volume. In this study,
we additionally controlled for BMI, ECOG score, Karnofsky
score, types of treatment modalities, and surgical margin status.
It should be noted that by accounting for different factors in
analyses potential differences in significance values will arise
and thus could also influence the determination of whether
COP‑MPV affects survival. Another key difference between
our study and other studies is the area of interest for cancers. In
our study various locations of cancer of the head and neck area
were included, whereas other studies mainly focused on areas
of higher specification or a particular type of carcinom (12‑14).

As a result, by considering different afflicted locations it may
explain why our significance scores were different from other
studies.
Of note, the study by Park et al (12) found that the
COP‑MPV was significantly associated with survival in their
multivariate analysis. However, we believe that their results
might be limited due to several reasons. Firstly, they had a small
sample size of patients; secondly, their multivariate model did
not account for important covariates such as adjuvant therapies and comorbidities which would have significantly biased
their results. Our results agree with certain aspects of their
study; they also found that tumor stage (P= 0.735) and nodal
stage (P=1.00) were not associated with COP‑MPV scores.
Nevertheless, we believe the work by Park et al (12) is the
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Table II. Multivariate Cox Regression Analysis of Event-Free
Survival.
Variable
Age
Sex
Male
Female
BMI
History of alcohol use
History of smoking
Overall ACE-27 score
ECOG score
Karnofsky score
100
90
80
≤70
Tumor primary location
Tumor differentiation
Well differentiated
Moderately
differentiated
Poorly differentiated
Staging pT
pT1
pT2
pT3
pT4
Staging pN
pN0
pN1
pN2
pN3
Adjuvant radiotherapy
Adjuvant
chemoradiotherapy
Surgical margin status
WBC
Hemoglobin
MPV
Platelet count
COP-MPV
0
1
2

Multivariate analysis
------------------------------------------------------------------HR
95% CI
P-value
Nsa

-

-

Reference
Nsa
Nsa
Nsa
Nsa
Nsa
Nsa

-

-

Nsa

-

-

Reference
2.37

1.17-4.84

0.0171b

Nsa

-

-

Reference
Nsa
Nsa
c

3.46-22.91 <0.0001b
-

Reference
3.41
3.30

1.11-10.47
1.23-8.86

0.0321
0.0177b

Nsa
Nsa

-

-

3.77
Nsa
0.62
2.16
Nsa

1.54-9.24
0.50-0.78
0.95-4.92
-

0.0037b
<0.0001b
0.0659
-

Reference
Nsa
Nsa

b

Not applicable.
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P>0.1, thus these were removed from the multivariate regression
model via backwards selection; bStatistically significant (P<0.05);
c
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model analysis. 95% CI, 95% confidence interval; HR, hazard ratio;
BMI, body‑mass index; ACE-27, adult comorbidity evaluation 27
score; ECOG, eastern cooperative oncology group score; WBC, white
blood cell count; MPV, mean platelet volume; COP-MPV, combination
of platelet count and mean platelet volume score; Ns, not significant.
a

first report of COP‑MPV for a HNC subsite. In our study, we
analyzed patients from all HNC subsites, in a larger sample
size than the previous study by Park et al (12).
We acknowledge several limitations in our study. Firstly,
this is a retrospective cohort study where some elements of
bias might be in the data. Secondly, considering that different
types of HNCs were included, each may have their own
prognostic characteristics. We are unable to definitely draw
a conclusion that the COP‑MPV is not effective in all HNC
subsites. Our study has several strengths: First, this includes
rigorous control for all prognostic covariates in our analyses;
Secondly, the included patients had similar treatment regimens
where all experienced curative intent surgery with or without
adjuvant radiation or chemotherapy; Third, unlike previously
mentioned literature, we used the latest staging system (AJCC
8th edition) in our study, which has been shown to have
improved prognostic discrimination between stages (18). It
should be acknowledged that the use of older staging criteria
by other studies might have affected their results. Most importantly, this study adds on to the literature for COP‑MPV as
this is the first comprehensive study examining the prognostic
utility of COP‑MPV in all HNC subsites.
In conclusion, we did not find COP‑MPV to be related to
the survival endpoint EFS. However, high quality prospective
studies should be considered and are needed to validate our
conclusions for COP‑MPV. At this time, we cannot recommend the COP‑MPV as a prognostic indicator in HNC.
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